<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-130795" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lipoprotein A</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zubair</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Indus Hospital &#x00026; Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Senthilkumaran</surname>
            <given-names>S</given-names>
          </name>
          <aff>Department of Emergency Medicine and Critical Care, Manian Medical Centre, Erode, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>S Senthilkumaran declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-130795.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lipoprotein(a), or&#x000a0;Lp(a), is an established and genetically determined risk factor for atherosclerosis, coronary artery disease, stroke, thrombosis, and aortic stenosis.<xref ref-type="bibr" rid="article-130795.r1">[1]</xref>&#x000a0;Structurally, it is a variant of low-density lipoprotein and features apolipoprotein(a), or apo(a), which is bound to apolipoprotein B-100, or apoB100. These 2 structures are assembled in the hepatocyte cell membranes and are bound by 1 disulfide bridge.<xref ref-type="bibr" rid="article-130795.r2">[2]</xref>&#x000a0;The electrophoretic mobility of Lp(a) is&#x000a0;typically pre-&#x003b2; but can vary between that of low-density lipoprotein (&#x003b2;) and albumin (pre-&#x003b1;).<xref ref-type="bibr" rid="article-130795.r3">[3]</xref></p>
        <p>Plasma concentrations of Lp(a) and the apo(a) isoform are inversely related.<xref ref-type="bibr" rid="article-130795.r4">[4]</xref>&#x000a0;The variation in isoforms is induced by the number of kringle IV repeats in the LP(a) gene. The variation in kringle units leads to the variable levels of Lp(a)&#x000a0;observed&#x000a0;in the general population. In general, individuals with fewer kringle repeats tend to have smaller Lp(a) particles but higher serum levels. In addition, larger isoforms of apo(a) lead to an increased accumulation of its precursor intracellularly within the endoplasmic reticulum.<xref ref-type="bibr" rid="article-130795.r5">[5]</xref>&#x000a0;</p>
        <p>Lp(a) levels &#x0003e;50 mg/dL are associated with an increased risk of cardiovascular diseases.<xref ref-type="bibr" rid="article-130795.r2">[2]</xref>&#x000a0;Internationally, there is a general disagreement on screening guidelines. Screening patients for elevated Lp(a) levels could help identify those who need more aggressive lipid therapy and cardiovascular disease risk management. The suggestion has been made that, for younger patients, coronary artery disease could be explained by Lp(a), with or without other risk factors.<xref ref-type="bibr" rid="article-130795.r6">[6]</xref></p>
        <p>No specific therapy exists for treating elevated Lp(a). Most generalized screening aims to identify elevated Lp(a) as an existing risk factor, followed by subsequent optimization of overall cardiac health as the primary treatment. While certain medications such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and niacin directly lower Lp(a) levels, there is no&#x000a0;Food and Drug Administration (FDA)-approved medication for the treatment of elevated Lp(a). Further research will contribute to the improvement of both screening guidelines and treatment modalities.<xref ref-type="bibr" rid="article-130795.r7">[7]</xref></p>
      </sec>
      <sec id="article-130795.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>Elevated Lp(a) levels are associated with an increased risk of cardiovascular disease and stroke.<xref ref-type="bibr" rid="article-130795.r6">[6]</xref>&#x000a0;The increased risk has generally been attributed to the atherosclerotic and thrombotic properties of this lipoprotein.</p>
        <p>Lp(a) levels are also considered to be determined genetically. Lp(a) gene polymorphisms generally lead to highly variable Lp(a) levels within the population,&#x000a0;ranging from &#x0003c;1 mg/dL to &#x0003e;1000 mg/dL. On average, individuals of African descent tend to have higher Lp(a) levels compared to those of White and Asian racial backgrounds.<xref ref-type="bibr" rid="article-130795.r8">[8]</xref><xref ref-type="bibr" rid="article-130795.r2">[2]</xref>&#x000a0;Patients with Lp(a) levels &#x0003e;50 mg/dL are considered to have an&#x000a0;increased risk of heart disease.<xref ref-type="bibr" rid="article-130795.r9">[9]</xref>&#x000a0;To date, there is no convincing evidence that mild-to-moderate elevations (&#x0003c;50 mg/dL) lead to an increased&#x000a0;risk of heart disease or stroke.&#x000a0;</p>
      </sec>
      <sec id="article-130795.s3" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Lp(a) is a distinct lipoprotein structurally related to low-density lipoprotein, containing an<bold>&#x000a0;</bold>apoB100 per particle and sharing a similar lipid composition.&#x000a0;Lp(a) also includes a carbohydrate-rich protein called apo(a), which is covalently bound to apo B 100 through a disulfide linkage.<xref ref-type="bibr" rid="article-130795.r2">[2]</xref> Apo(a) exhibits significant sequence homology with plasminogen; however, unlike plasminogen, it is not an active protease.<xref ref-type="bibr" rid="article-130795.r10">[10]</xref> Apo(a) contains a high degree of variation in its polypeptide chain length because of a variable number of kringle domains.<xref ref-type="bibr" rid="article-130795.r8">[8]</xref>&#x000a0;Plasminogen contains 5 kringle domains,&#x000a0;whereas&#x000a0;apo(a) contains only kringle types 4 and 5. There are 10 distinct classes of kringle IV-like domains in apo(a) that differ in amino acid sequences. Kringle IV type 1 and kringle IV types 3 to 10 are present as a single copy,&#x000a0;whereas kringle IV type 2 exists in varying numbers of repeats&#x000a0;(1 to &#x0003e;40). Thus, there are different-sized isoforms of apo(a) classically described as either large, high molecular weight or small, low molecular weight forms.<xref ref-type="bibr" rid="article-130795.r11">[11]</xref></p>
        <p>Paradoxically, due to the ease of hepatic production and secretion of the low molecular weight isoforms compared to high molecular weight isoforms, there can be a significant discordance between Lp(a) mass and Lp(a) particle (Lp(a)-P) concentrations. At the same Lp(a) mass, those with low molecular weight isoforms will have a higher Lp(a)-P concentration&#x000a0;compared to those with high molecular weight isoforms.<xref ref-type="bibr" rid="article-130795.r12">[12]</xref>&#x000a0;Low molecular weight isoforms are believed to be a significant cause of cardiovascular disease&#x000a0;compared to high molecular weight isoforms. However, this may be primarily related to their&#x000a0;higher Lp(a)-P concentration rather than anything inherent in the particle. Adding to the complexity is the codominant type of inheritance that occurs with Lp(a), with patients frequently having 2 different types of apo(a)-size isoforms expressed differently.<xref ref-type="bibr" rid="article-130795.r13">[13]</xref></p>
        <p>According to genetic and epidemiological studies, Lp(a) is considered pro-atherosclerotic, pro-inflammatory, pro-thrombotic, and anti-fibrinolytic.<xref ref-type="bibr" rid="article-130795.r6">[6]</xref> Lp(a) increases the expression of vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, thereby promoting the adhesion of monocytes to the endothelium and initiating atherosclerotic plaque formation.<xref ref-type="bibr" rid="article-130795.r14">[14]</xref>&#x000a0;Lp(a)&#x000a0;exhibits a&#x000a0;higher affinity for the vascular wall, proteoglycans, and fibronectin on the endothelial cell surface&#x000a0;compared to low-density lipoprotein cholesterol and other apo B-containing lipoproteins. This leads to the accumulation of Lp(a) in the arterial intima, contributing to the development of atherosclerotic lesions. Macrophages can take up Lp(a), leading to the formation of foam cells, which is a hallmark of early atherosclerosis.<xref ref-type="bibr" rid="article-130795.r15">[15]</xref></p>
        <p>Because of&#x000a0;its structure, Lp(a) leads to reduced fibrinolysis. Specifically, apo(a) carries a structure similar to tissue plasminogen activator and plasminogen. This similarity allows it to compete with plasminogen for its specific binding site, thereby interfering with its function and leading to reduced fibrinolysis.<xref ref-type="bibr" rid="article-130795.r16">[16]</xref> Thrombogenesis is also stimulated by Lp(a) as it leads to increased plasminogen activator inhibitor-1. The potential&#x000a0;benefits of&#x000a0;Lp(a) for the human body remain uncertain.<xref ref-type="bibr" rid="article-130795.r17">[17]</xref>&#x000a0;A theory&#x000a0;suggests&#x000a0;that Lp(a) has a role in the healing of wounds. However, individuals with significantly lower Lp(a) levels do not appear to have long-term health risks.<xref ref-type="bibr" rid="article-130795.r18">[18]</xref></p>
      </sec>
      <sec id="article-130795.s4" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>Serum or plasma is generally acceptable for measuring Lp(a) levels.&#x000a0;The serum or plasma should be separated from cells as soon as possible, within 2 hours. Fasting is not required for Lp(a) measurement, and despite being genetically determined, inflammation may influence Lp(a) levels.<xref ref-type="bibr" rid="article-130795.r19">[19]</xref>&#x000a0;The specific specimen requirements provided by the laboratory performing the test should be&#x000a0;followed to ensure accurate and reliable results. Specimens that are grossly hemolyzed, lipemic, or icteric may be rejected.<xref ref-type="bibr" rid="article-130795.r20">[20]</xref></p>
      </sec>
      <sec id="article-130795.s5" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>Lp(a) is screened through&#x000a0;a serum blood test. The general purpose of screening for Lp(a) is to identify individuals at higher risk for cardiovascular disease. Today, there is variability in expert opinion on when to screen for elevated Lp(a). The National Lipid Association (NLA) recommends&#x000a0;considering&#x000a0;Lp(a) testing in cases&#x000a0;with a significant family history of premature atherosclerotic cardiovascular disease among first-degree relatives, personal history of premature atherosclerotic cardiovascular disease, and severe primary hyperlipidemia. The NLA also recommends considering&#x000a0;Lp(a) testing to aid in the process of shared decision-making regarding statin therapy for individuals in the borderline atherosclerotic cardiovascular disease risk category.<xref ref-type="bibr" rid="article-130795.r21">[21]</xref>&#x000a0;The American College of Cardiology and the American Heart Association do not have official Lp(a) screening guidelines.&#x000a0;Canadian guidelines recommend universal screening for Lp(a).<xref ref-type="bibr" rid="article-130795.r22">[22]</xref></p>
        <p>The European Atherosclerosis Society (EAS) has&#x000a0;established guidelines outlining situations where screening for Lp(a) is typically advised. These criteria include&#x000a0;patients with a personal history of premature cardiovascular disease, those experiencing recurrent cardiovascular disease&#x000a0;events while on statin therapy, and individuals with a &#x02265;10% 10-year risk of cardiovascular disease. A family history of premature cardiovascular disease, elevated Lp(a), and familial hypercholesterolemia are also indications for Lp(a) screening. The European Society of Cardiology (ESC) recommends screening for Lp(a) at least once&#x000a0;during&#x000a0;an individual's lifetime.<xref ref-type="bibr" rid="article-130795.r23">[23]</xref></p>
        <p>No recommendations or guidelines exist for testing Lp(a) in pediatric patient populations, mainly due to insufficient data on Lp(a) within this age group. Further research is required in this patient population to help develop better screening guidelines.&#x000a0;</p>
      </sec>
      <sec id="article-130795.s6" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Several commercially available immunoassays, such as enzyme-linked immunosorbent assay (ELISA), immunoturbidometric, and immunonephelometric assays, are used to quantify Lp(a). Most of these assays, except for ELISA,&#x000a0;use&#x000a0;polyclonal antibodies from various animal species. Commercially available, direct-binding, sandwich-type ELISAs typically&#x000a0;combine monoclonal and polyclonal antibodies.<xref ref-type="bibr" rid="article-130795.r24">[24]</xref></p>
        <p>The precise measurement of Lp(a) in human plasma is significantly impacted by the structural variability of Lp(a) that results from apo(a) size heterogeneity.&#x000a0;Different Lp(a) particles contain varying quantities of repeating antigenic determinants, and the responsiveness of the antibodies against these repeated epitopes can change depending on the size of the apo(a) particle. As a consequence, immunoassays using polyclonal or monoclonal antibodies specifically targeting kringle IV type 2 epitopes will tend to underestimate apo(a) concentration in samples with apo(a) of smaller size&#x000a0;compared to the apo(a) present in the assay calibrator, and overestimate the apo(a) concentration in samples with apo(a) of larger size.<xref ref-type="bibr" rid="article-130795.r2">[2]</xref>&#x000a0;To address these challenges, researchers have developed isoform-independent assays that aim to accurately measure Lp(a) without the impact of apo(a) size polymorphism. For example, a monoclonal antibody (a-40) targeting a unique epitope located in KIV 9 of apo(a) has been used in the development of an ELISA that accurately measures Lp(a) without the impact of apo(a) size polymorphism.<xref ref-type="bibr" rid="article-130795.r25">[25]</xref></p>
        <p>In summary, the varying immunoreactivity of antibodies to different apo(a) size isoforms can lead to inaccurate measurements of Lp(a) levels, leading to overestimating or underestimating the true values. This highlights the importance of using standardized assays and considering the impact of apo(a) size heterogeneity when interpreting Lp(a) measurements.<xref ref-type="bibr" rid="article-130795.r24">[24]</xref></p>
      </sec>
      <sec id="article-130795.s7" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Ethanol consumption, niacin supplements, aspirin, and oral estrogen supplementation&#x000a0;may affect the results' accuracy.&#x000a0;The duration for which an individual should stop taking medications or supplements that can interfere with Lp(a) analysis results may vary.<xref ref-type="bibr" rid="article-130795.r26">[26]</xref>&#x000a0;The specific instructions provided by the laboratory performing the test should be followed.<xref ref-type="bibr" rid="article-130795.r27">[27]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-130795.s8" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>Lp(a) is traditionally measured in mg/dL, whereas&#x000a0;ideally, it should be measured in nmol/L due to large interindividual size heterogeneity resulting from kringle IV type 2.<xref ref-type="bibr" rid="article-130795.r28">[28]</xref> The desirable and optimal Lp(a) test result range&#x000a0;is &#x0003c;14 mg/dL. The highest risk range is &#x0003e;50 mg/dL. Patients with an Lp(a) of 14&#x000a0;to 30 mg/dL are considered to be at borderline risk, whereas those within the range of 31&#x000a0;to 50 mg/dL are at high risk.<xref ref-type="bibr" rid="article-130795.r29">[29]</xref></p>
        <p>Lp(a) levels directly contribute to serum low-density lipoprotein levels because Lp(a) particles contain low-density lipoprotein particles.&#x000a0;Laboratory testing for Lp(a) often also includes lipoprotein-X (LpX) levels reported as a separate result. These compounds consist of cholesterol and phospholipids, and high levels are associated with cholestasis and hyperviscosity syndromes.<xref ref-type="bibr" rid="article-130795.r30">[30]</xref></p>
        <p>Since&#x000a0;Lp(a) is genetically transmitted, screening is considered for&#x000a0;young individuals<bold>&#x000a0;</bold>whose parents have&#x000a0;high Lp(a) levels; conversely, reverse cascade screening is recommended when a child is found to have an elevated level of Lp(a).<xref ref-type="bibr" rid="article-130795.r31">[31]</xref></p>
      </sec>
      <sec id="article-130795.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The primary reason for screening patients for Lp(a) is to help further identify those at high risk for heart disease, especially in the absence of other major risk factors. In addition, it also helps identify those patients who may require more intensive lipid therapy.<xref ref-type="bibr" rid="article-130795.r32">[32]</xref> Patients with significantly elevated Lp(a) levels should generally be treated to&#x000a0;achieve a target of &#x0003c;50 mg/dL.&#x000a0;A treatment option is daily niacin, which may lower Lp(a) levels by 20% to 30%. However, niacin has not been associated with improved cardiac outcomes despite its known beneficial effect on all lipid markers and Lp(a).<xref ref-type="bibr" rid="article-130795.r33">[33]</xref></p>
        <p>Statins have shown mixed results and, in some cases, have been shown to increase Lp(a).<xref ref-type="bibr" rid="article-130795.r34">[34]</xref>&#x000a0;Nonetheless, statins are a primary treatment option for patients with hyperlipidemia. High Lp(a) levels may indicate the need for more intensive statin therapy to optimize a patient's low-density lipoprotein level and reduce their risk for coronary artery disease. PCSK9 inhibitors are also an option for lowering Lp(a). A meta-analysis showed PCSK9 inhibitors lowered Lp(a) by 26%, in addition to improved cardiac outcomes.<xref ref-type="bibr" rid="article-130795.r35">[35]</xref>&#x000a0;Cumulatively, it is not yet evident if elevated Lp(a) remains to be an independent significant risk factor even after successful treatment.&#x000a0;</p>
        <p>Less commonly used options include lipid apheresis and<bold>&#x000a0;</bold>an investigational therapy called antisense therapy. Generally, lipid apheresis may be reserved for the most severe refractory cases&#x000a0;and has a very limited role in treating elevated Lp(a). Apheresis will also cause transient declines in Lp(a) levels and serum levels can generally begin to climb back up.<xref ref-type="bibr" rid="article-130795.r6">[6]</xref></p>
        <p>Hormonal drugs may improve Lp(a) levels but are not necessarily associated with improved cardiovascular outcomes. Estrogen can improve Lp(a) levels and has been discussed in the context of improving potential cardiac risk profiles, but it is not currently used as a therapy to improve lipid markers. Estrogen also carries other potential risks for certain patient populations and is unlikely to&#x000a0;be established as a treatment modality.<xref ref-type="bibr" rid="article-130795.r36">[36]</xref>&#x000a0;</p>
        <p>Testosterone replacement therapy has been shown to lower Lp(a) levels. Further research on testosterone replacement therapy is necessary to&#x000a0;draw a conclusion regarding&#x000a0;its role in preventative cardiology, as the cumulative evidence is currently unclear. Of note, testosterone replacement therapy can lead to lower HDL levels, thereby increasing the risk of atherosclerosis.<xref ref-type="bibr" rid="article-130795.r37">[37]</xref>&#x000a0;L-carnitine may also lower Lp(a) levels, but it has been associated with increased levels of trimethylamine <italic toggle="yes">N</italic>-oxide (TMAO), potentially leading to atherosclerosis.<xref ref-type="bibr" rid="article-130795.r38">[38]</xref>&#x000a0;More therapies continue to arise, and a key factor will be whether or not cardiac outcomes are improved.<xref ref-type="bibr" rid="article-130795.r39">[39]</xref>&#x000a0;Further research is needed to help identify medications that directly decrease Lp(a) levels.&#x000a0;</p>
        <p>Lp(a) levels are primarily determined by genetics, but some lifestyle changes can help reduce the risk of cardiovascular disease associated with high Lp(a) levels.<xref ref-type="bibr" rid="article-130795.r40">[40]</xref>&#x000a0;Consuming more vegetables, fruits, nuts, and flaxseed may help decrease Lp(a) levels. In a 2-week study&#x000a0;involving 10 individuals, a diet rich in these foods led to a reduction of Lp(a) levels by 24%.<xref ref-type="bibr" rid="article-130795.r41">[41]</xref> In&#x000a0;a 6-week study involving 38 individuals with high Lp(a) levels, ground flaxseed was found to reduce Lp(a) levels by ~7%. Similarly, in another 10-week study&#x000a0;involving 62 individuals, Lp(a) decreased by 14%.<xref ref-type="bibr" rid="article-130795.r42">[42]</xref></p>
        <p>The relationship between exercise and Lp(a) levels is still not fully understood. Some studies suggest that moderate exercise has little effect on serum Lp(a) concentration.&#x000a0;However, other studies suggest that intense load-bearing exercise training, such as distance running or weight lifting, may increase serum Lp(a) levels over several months to years.<xref ref-type="bibr" rid="article-130795.r43">[43]</xref></p>
      </sec>
      <sec id="article-130795.s10" sec-type="Quality Control and Lab Safety&#x0000d;&#x0000a;">
        <title>Quality Control and Lab Safety
</title>
        <p>The clinical laboratory is involved in many aspects of the analytical phase to ensure high-quality testing.<xref ref-type="bibr" rid="article-130795.r44">[44]</xref>&#x000a0;Overseeing quality management procedures in the clinical laboratory includes the initial step of controlling a procedure, quality control (QC), and quality assurance, a broader component providing proficiency testing, personnel competency testing, inventory monitoring, and equipment calibration and maintenance.<xref ref-type="bibr" rid="article-130795.r45">[45]</xref> Internal QC ensures that measurement procedures meet specifications when patient testing occurs. QC samples are measured at intervals along with patient samples. Recovery of the expected target values for the QC samples allows the laboratory to verify that a measurement procedure is working correctly and the results for patient samples can be reported.<xref ref-type="bibr" rid="article-130795.r46">[46]</xref></p>
        <p>For non-waived tests, laboratory regulations require analysis of at least 2&#x000a0;levels of QCl materials once every 24 hours as a minimum requirement. If necessary, laboratories can assay QC samples more frequently to ensure accurate results. QC samples should be assayed after calibration or maintenance of an analyzer to verify the correct method performance.<xref ref-type="bibr" rid="article-130795.r47">[47]</xref></p>
        <p>Considerations in the design of a QC plan include the analytical performance capability of a measurement procedure and the risk of harm to a patient that might occur&#x000a0;from&#x000a0;erroneous laboratory test results used for clinical care decisions. An erroneous laboratory test result is a hazardous condition that may or may not cause harm to a patient depending on how the laboratory test is used for patient monitoring and treatment, the magnitude of the error, and subsequent action or inaction taken by a clinical care provider.<xref ref-type="bibr" rid="article-130795.r48">[48]</xref></p>
        <p>The laboratory must participate in the external&#x000a0;QC or proficiency testing program.<xref ref-type="bibr" rid="article-130795.r49">[49]</xref> This is a regulatory requirement published by the Centers for Medicare and Medicaid Services (CMS) in the Clinical Laboratory Improvement Amendments (CLIA) regulations.&#x000a0;External QC, also called external quality assessment or proficiency testing, is an assessment process in which samples are received from an independent external organization, and the laboratory does not know the expected values. The results for the external quality assessment or proficiency testing&#x000a0;samples are compared with target values assigned to the samples to verify that a laboratory&#x02019;smeasurement procedures meet&#x000a0;the expected performance.<xref ref-type="bibr" rid="article-130795.r50">[50]</xref> In addition to internal and external QC, the results obtained from testing patient samples (for example, medians of patient results) can be used to assess and monitor the performance of measurement procedures.<xref ref-type="bibr" rid="article-130795.r51">[51]</xref></p>
        <p>Laboratory personnel should wear appropriate personal protective equipment such as lab coats, gloves, safety goggles, and masks to protect against chemical splashes, biological hazards, and other potential risks in the laboratory.<xref ref-type="bibr" rid="article-130795.r52">[52]</xref>&#x000a0;Material safety data sheets should be followed to ensure proper handling, storage, and disposal of chemicals. Other QC procedures include regular inspection and maintenance of laboratory equipment to ensure they are in proper working condition, adhering to&#x000a0;regulations and guidelines for disposing of&#x000a0;hazardous waste materials, using&#x000a0;designated waste disposal containers for different types of waste, washing hands thoroughly before and after working in the laboratory, and refraining from eating, drinking, and applying cosmetics in the lab area.<xref ref-type="bibr" rid="article-130795.r53">[53]</xref>&#x000a0;All personnel working in the clinical laboratory should actively maintain a safe working environment and adhere to established safety protocols to ensure the well-being of all individuals involved.<xref ref-type="bibr" rid="article-130795.r54">[54]</xref></p>
      </sec>
      <sec id="article-130795.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Lp(a) is a genetically determined independent risk factor for the development of atherosclerosis. Today, it is unclear if direct interventions and treatments of Lp(a) help change patient outcomes from a cardiac standpoint. However, given that it is a known risk factor for heart disease, a team-based effort is required to minimize the patient's other cardiac risks to improve cardiac outcomes.</p>
        <p>Lipid therapy often requires an interprofessional&#x000a0;healthcare team approach to achieve maximum success for the patient. The clinician oversees the prescription of lipid therapy medications, installs appropriate lifestyle modifications, and makes appropriate referrals. Treatment of more advanced lipid disorders benefits from having a pharmacist and dietitian involved to ensure appropriate medication protocols are in place&#x000a0;and optimized dietary interventions are instituted. This team-based effort is vital in preventative cardiology for the patient population.</p>
        <p>Lp(a) testing is an essential tool in cardiovascular risk assessment, requiring the collective efforts of a multidisciplinary healthcare team. By fostering communication, standardizing protocols, and emphasizing patient education, healthcare teams can enhance their ability to provide comprehensive care, ultimately leading to improved patient outcomes in cardiovascular health.</p>
      </sec>
      <sec id="article-130795.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=130795&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=130795">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/130795/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=130795">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-130795.s13">
        <title>References</title>
        <ref id="article-130795.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scipione</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Koschinsky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Boffa</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-54</page-range>
            <pub-id pub-id-type="pmid">29262744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maranh&#x000e3;o</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Strunz</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Pileggi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein (a): structure, pathophysiology and clinical implications.</article-title>
            <source>Arq Bras Cardiol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-84</page-range>
            <pub-id pub-id-type="pmid">25120086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamauchi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Electrophoretic Analysis of Serum Lipoproteins: Its Usefulness and Problems].</article-title>
            <source>Rinsho Byori</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>11</issue>
            <fpage>1079</fpage>
            <page-range>1079-87</page-range>
            <pub-id pub-id-type="pmid">27509725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cain</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ikewaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Talley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zech</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Usher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.</article-title>
            <source>J Clin Invest</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>93</volume>
            <issue>6</issue>
            <fpage>2758</fpage>
            <page-range>2758-63</page-range>
            <pub-id pub-id-type="pmid">8201014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enas</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Varkey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dharmarajan</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Pare</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bahl</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.</article-title>
            <source>Indian Heart J</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-112</page-range>
            <pub-id pub-id-type="pmid">31280836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bor&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andreotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amarenco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kovanen</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kuivenhoven</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lesnik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Masana</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tokg&#x000f6;zoglu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tybj&#x000e6;rg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <collab>European Atherosclerosis Society Consensus Panel</collab>
            </person-group>
            <article-title>Lipoprotein(a) as a cardiovascular risk factor: current status.</article-title>
            <source>Eur Heart J</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>23</issue>
            <fpage>2844</fpage>
            <page-range>2844-53</page-range>
            <pub-id pub-id-type="pmid">20965889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Banach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.</article-title>
            <source>J Thorac Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>E78</fpage>
            <page-range>E78-E82</page-range>
            <pub-id pub-id-type="pmid">28203441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boerwinkle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leffert</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lackner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chiesa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.</article-title>
            <source>J Clin Invest</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-60</page-range>
            <pub-id pub-id-type="pmid">1386087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klausen</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Sj&#x000f8;l</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Gerdes</surname>
                <given-names>LU</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lemming</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schroll</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faergeman</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study.</article-title>
            <source>Atherosclerosis</source>
            <year>1997</year>
            <month>Jul</month>
            <day>11</day>
            <volume>132</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">9247362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romagnuolo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marcovina</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Boffa</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Koschinsky</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).</article-title>
            <source>J Lipid Res</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>625</fpage>
            <page-range>625-34</page-range>
            <pub-id pub-id-type="pmid">24478033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandmark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tigerstr&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akerud</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Althage</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antonsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blaho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bodin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bostr&#x000f6;m</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dahl&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Evertsson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fex</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fjellstr&#x000f6;m</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gustafsson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hersl&#x000f6;f</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jarkvist</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalies</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Karlsson Svalstedt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kartberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Legnehed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ridderstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosengren</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sabirsh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thelin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vinblad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wellner</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000d6;stlund-Lindqvist</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Knecht</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function.</article-title>
            <source>J Biol Chem</source>
            <year>2020</year>
            <month>Apr</month>
            <day>10</day>
            <volume>295</volume>
            <issue>15</issue>
            <fpage>5136</fpage>
            <page-range>5136-5151</page-range>
            <pub-id pub-id-type="pmid">32132173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Coll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Marcovina</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>PHR</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2019</year>
            <month>Apr</month>
            <day>02</day>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>e011781</fpage>
            <pub-id pub-id-type="pmid">30897995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reyes-Soffer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Berglund</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Duell</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Heffron</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kamstrup</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Marcovina</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Yeang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koschinsky</surname>
                <given-names>ML</given-names>
              </name>
              <collab>American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease</collab>
            </person-group>
            <article-title>Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>e48</fpage>
            <page-range>e48-e60</page-range>
            <pub-id pub-id-type="pmid">34647487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cook-Mills</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Marchese</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Abdala-Valencia</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants.</article-title>
            <source>Antioxid Redox Signal</source>
            <year>2011</year>
            <month>Sep</month>
            <day>15</day>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>1607</fpage>
            <page-range>1607-38</page-range>
            <pub-id pub-id-type="pmid">21050132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.</article-title>
            <source>Aging Dis</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>491</fpage>
            <page-range>491-520</page-range>
            <pub-id pub-id-type="pmid">35371605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angl&#x000e9;s-Cano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de la Pe&#x000f1;a D&#x000ed;az</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loyau</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of fibrinolysis by lipoprotein(a).</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2001</year>
            <volume>936</volume>
            <fpage>261</fpage>
            <page-range>261-75</page-range>
            <pub-id pub-id-type="pmid">11460483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ugov&#x00161;ek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x00160;ebe&#x00161;tjen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.</article-title>
            <source>Biomolecules</source>
            <year>2021</year>
            <month>Dec</month>
            <day>24</day>
            <volume>12</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35053174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ors&#x000f3;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.</article-title>
            <source>Clin Res Cardiol Suppl</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>Suppl 1</issue>
            <fpage>31</fpage>
            <page-range>31-37</page-range>
            <pub-id pub-id-type="pmid">28188431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Langsted</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kolovou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bruckert</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Sypniewska</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bor&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cobbaert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>von Eckardstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kamstrup</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Pulkki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kronenberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Remaley</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Rifai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Langlois</surname>
                <given-names>M</given-names>
              </name>
              <collab>European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative</collab>
            </person-group>
            <article-title>Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Jul</month>
            <day>01</day>
            <volume>37</volume>
            <issue>25</issue>
            <fpage>1944</fpage>
            <page-range>1944-58</page-range>
            <pub-id pub-id-type="pmid">27122601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikolac</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Lipemia: causes, interference mechanisms, detection and management.</article-title>
            <source>Biochem Med (Zagreb)</source>
            <year>2014</year>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-67</page-range>
            <pub-id pub-id-type="pmid">24627715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Koschinsky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>McNeal</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.</article-title>
            <source>J Clin Lipidol</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>374</fpage>
            <page-range>374-392</page-range>
            <pub-id pub-id-type="pmid">31147269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Beam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiella-Tommasino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Pajares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ndumele</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jun</month>
            <day>18</day>
            <volume>139</volume>
            <issue>25</issue>
            <fpage>e1046</fpage>
            <page-range>e1046-e1081</page-range>
            <pub-id pub-id-type="pmid">30565953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baigent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Koskinas</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Casula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badimon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ference</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mihaylova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Riccardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tokgozoglu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>O</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.</article-title>
            <source>Eur Heart J</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-188</page-range>
            <pub-id pub-id-type="pmid">31504418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcovina</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein (a) measurements for clinical application.</article-title>
            <source>J Lipid Res</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>526</fpage>
            <page-range>526-37</page-range>
            <pub-id pub-id-type="pmid">26637278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcovina</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Navabi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Witztum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tsimikas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a).</article-title>
            <source>J Lipid Res</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>100239</fpage>
            <pub-id pub-id-type="pmid">35688187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kostner</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>M&#x000e4;rz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kostner</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>When should we measure lipoprotein (a)?</article-title>
            <source>Eur Heart J</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>42</issue>
            <fpage>3268</fpage>
            <page-range>3268-76</page-range>
            <pub-id pub-id-type="pmid">23735860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herzum</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Giehl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soufi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Junclas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wahl</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Interference in a homogeneous assay for low-density lipoprotein cholesterol by lipoprotein X.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2007</year>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>667</fpage>
            <page-range>667-71</page-range>
            <pub-id pub-id-type="pmid">17484632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cegla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>France</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marcovina</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Neely</surname>
                <given-names>RDG</given-names>
              </name>
            </person-group>
            <article-title>Lp(a): When and how to measure it.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-21</page-range>
            <pub-id pub-id-type="pmid">33040574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leitersdorf</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Blaha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Morishita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsimikas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kozlovski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lesogor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thuren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shibasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Silveira</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Meunch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vijan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bruun</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <collab>Lp(a)HERITAGE Investigators</collab>
            </person-group>
            <article-title>Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.</article-title>
            <source>Open Heart</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36252994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00106;wikli&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mickiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kortas-Stempak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuchta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mucha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makowiecki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gliwi&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewandowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>P&#x00105;czek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fija&#x00142;kowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grucha&#x00142;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.</article-title>
            <source>J Med Biochem</source>
            <year>2020</year>
            <month>Sep</month>
            <day>02</day>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-289</page-range>
            <pub-id pub-id-type="pmid">33269016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakraborty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vorster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a).</article-title>
            <source>Am J Prev Cardiol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>10</volume>
            <fpage>100343</fpage>
            <pub-id pub-id-type="pmid">35517871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saeedi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Frohlich</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lipoprotein (a), an independent cardiovascular risk marker.</article-title>
            <source>Clin Diabetes Endocrinol</source>
            <year>2016</year>
            <volume>2</volume>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">28702242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boden</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Sidhu</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>The therapeutic role of niacin in dyslipidemia management.</article-title>
            <source>J Cardiovasc Pharmacol Ther</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-58</page-range>
            <pub-id pub-id-type="pmid">24363242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsimikas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gordts</surname>
                <given-names>PLSM</given-names>
              </name>
              <name>
                <surname>Nora</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yeang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Witztum</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Statin therapy increases lipoprotein(a) levels.</article-title>
            <source>Eur Heart J</source>
            <year>2020</year>
            <month>Jun</month>
            <day>21</day>
            <volume>41</volume>
            <issue>24</issue>
            <fpage>2275</fpage>
            <page-range>2275-2284</page-range>
            <pub-id pub-id-type="pmid">31111151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navarese</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kolodziejczak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schulze</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gurbel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Tantry</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Brockmeyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kandzari</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Kubica</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kubica</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Volpe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agewall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kereiakes</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kelm</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.</article-title>
            <source>Ann Intern Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>07</day>
            <volume>163</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-51</page-range>
            <pub-id pub-id-type="pmid">25915661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vittinghoff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Budoff</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cedars</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Lobo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Merriam</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Naftolin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.</article-title>
            <source>Am J Med</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-205</page-range>
            <pub-id pub-id-type="pmid">21396500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zmunda</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Dickenson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bausserman</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Testosterone decreases lipoprotein(a) in men.</article-title>
            <source>Am J Cardiol</source>
            <year>1996</year>
            <month>Jun</month>
            <day>01</day>
            <volume>77</volume>
            <issue>14</issue>
            <fpage>1244</fpage>
            <page-range>1244-7</page-range>
            <pub-id pub-id-type="pmid">8651107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samulak</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sawicka</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Hartmane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grinberga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pugovics</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lysiak-Szydlowska</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Olek</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>L-Carnitine Supplementation Increases Trimethylamine-N-Oxide but not Markers of Atherosclerosis in Healthy Aged Women.</article-title>
            <source>Ann Nutr Metab</source>
            <year>2019</year>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-17</page-range>
            <pub-id pub-id-type="pmid">30485835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serban</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sahebkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mikhailidis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blaha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Andrica</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Borza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Rysz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hazen</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Banach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Jan</month>
            <day>12</day>
            <volume>6</volume>
            <fpage>19188</fpage>
            <pub-id pub-id-type="pmid">26754058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nurmohamed</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Kraaijenhof</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>ESG</given-names>
              </name>
            </person-group>
            <article-title>Lp(a): a New Pathway to Target?</article-title>
            <source>Curr Atheroscler Rep</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>831</fpage>
            <page-range>831-838</page-range>
            <pub-id pub-id-type="pmid">36066785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enkhmaa</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kris-Etherton</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Berglund</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?</article-title>
            <source>Nutrients</source>
            <year>2020</year>
            <month>Jul</month>
            <day>07</day>
            <volume>12</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">32646066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahebkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katsiki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>&#x0017d;</given-names>
              </name>
            </person-group>
            <article-title>Flaxseed Supplementation Reduces Plasma Lipoprotein(a) Levels: A Meta-Analysis.</article-title>
            <source>Altern Ther Health Med</source>
            <year>2021</year>
            <month>May</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>50</fpage>
            <page-range>50-53</page-range>
            <pub-id pub-id-type="pmid">31634874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackinnon</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Hubinger</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Effects of exercise on lipoprotein(a).</article-title>
            <source>Sports Med</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-24</page-range>
            <pub-id pub-id-type="pmid">10461709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plebani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Errors in clinical laboratories or errors in laboratory medicine?</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2006</year>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>750</fpage>
            <page-range>750-9</page-range>
            <pub-id pub-id-type="pmid">16729864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Role of a quality management system in improving patient safety - laboratory aspects.</article-title>
            <source>Clin Biochem</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>13-14</issue>
            <fpage>1187</fpage>
            <page-range>1187-93</page-range>
            <pub-id pub-id-type="pmid">23648455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ric&#x000f3;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fernandez-Calle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Westgard</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Internal quality control - past, present and future trends.</article-title>
            <source>Adv Lab Med</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-262</page-range>
            <pub-id pub-id-type="pmid">37362142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ezzelle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodriguez-Chavez</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Darden</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Stirewalt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunwar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hitchcock</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories.</article-title>
            <source>J Pharm Biomed Anal</source>
            <year>2008</year>
            <month>Jan</month>
            <day>07</day>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-29</page-range>
            <pub-id pub-id-type="pmid">18037599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nichols</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Laboratory quality control based on risk management.</article-title>
            <source>Ann Saudi Med</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-8</page-range>
            <pub-id pub-id-type="pmid">21623049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>External quality assessment in resource-limited countries.</article-title>
            <source>Biochem Med (Zagreb)</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-109</page-range>
            <pub-id pub-id-type="pmid">28392732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ames</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Still</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Twomey</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>External quality assessment: best practice.</article-title>
            <source>J Clin Pathol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>8</issue>
            <fpage>651</fpage>
            <page-range>651-5</page-range>
            <pub-id pub-id-type="pmid">24621574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lock</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>My approach to internal quality control in a clinical immunology laboratory.</article-title>
            <source>J Clin Pathol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>681</fpage>
            <page-range>681-4</page-range>
            <pub-id pub-id-type="pmid">16803947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meisenhelder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bursik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lunn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Laboratory safety.</article-title>
            <source>Curr Protoc Hum Genet</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>Appendix 2</volume>
            <fpage>Appendix 2A</fpage>
            <pub-id pub-id-type="pmid">18428418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Biological safety in the medical laboratory.</article-title>
            <source>Hong Kong Med J</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>200</fpage>
            <pub-id pub-id-type="pmid">26045068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-130795.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drury</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Health and safety in the medical laboratory.</article-title>
            <source>Can J Med Technol</source>
            <year>1988</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-81</page-range>
            <pub-id pub-id-type="pmid">10289978</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
